Cargando…

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8(+) T cell responses capable of curing multi-focal cancer

BACKGROUND: High-dose radiotherapy (RT) is known to be immunogenic, but is rarely capable of driving clinically relevant abscopal antitumor immunity as monotherapy. RT is known to increase antigen presentation, type I/II interferon responses, and immune cell trafficking to irradiated tumors. Bempega...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walker, Joshua M, Rolig, Annah S, Charych, Deborah H, Hoch, Ute, Kasiewicz, Melissa J, Rose, Daniel C, McNamara, Michael J, Hilgart-Martiszus, Ian F, Redmond, William L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252958/ https://www.ncbi.nlm.nih.gov/pubmed/32457127 http://dx.doi.org/10.1136/jitc-2019-000464

Ejemplares similares

Synergistic antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 when combined with anti-PD-1 in murine tumor models
por: Murali, Addepalli, et al.
Publicado: (2015)

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
por: Charych, Deborah, et al.
Publicado: (2017)

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015)

Murine peripheral blood prognostic biomarkers for tumor survival following combination aCTLA-4 and aPD-1 treatment
por: Hilgart-Martiszus, Ian, et al.
Publicado: (2015)

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT
por: Rolig, Annah S, et al.
Publicado: (2022)

Galectin-3 inhibition using novel inhibitor GR-MD-02 improves survival and immune function while reducing tumor vasculature
por: Linch, Stefanie, et al.
Publicado: (2015)

Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models
por: Stirm, Kristin, et al.
Publicado: (2023)

Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma
por: Hennessy, Marlene, et al.
Publicado: (2020)

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment
por: Farhad, Mohammad, et al.
Publicado: (2018)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity
por: Sturgill, Elizabeth R., et al.
Publicado: (2021)

NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
por: Adkins, Chris E., et al.
Publicado: (2015)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
por: Hoch, Ute, et al.
Publicado: (2014)

Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody
por: Katoh, Yuki, et al.
Publicado: (2022)

Biomarkers of survival statistics (boss) analytical platform
por: McNamara, Michael, et al.
Publicado: (2015)

A twist in the tail
por: Guillemin, Karen, et al.
Publicado: (2014)

Synergism of calycosin and bone marrow-derived mesenchymal stem cells to combat podocyte apoptosis to alleviate adriamycin-induced focal segmental glomerulosclerosis
por: Hu, Qiong-Dan, et al.
Publicado: (2023)

Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts
por: Milovancev, Milan, et al.
Publicado: (2013)

EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021)

Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
por: Redmond, William L, et al.
Publicado: (2013)

Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells
por: McNamara, Michael J, et al.
Publicado: (2014)

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability
por: Sommermeyer, Daniel, et al.
Publicado: (2013)

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
por: Curti, Brendan D, et al.
Publicado: (2021)

THU485 The Impact Of Cured, Fried Bacon On The Reemergence From Breast Cancer Dormancy
por: Schane, Claire P, et al.
Publicado: (2023)

MicroRNA-214-5p protects against myocardial ischemia reperfusion injury through targeting the FAS ligand
por: Lu, Yuan, et al.
Publicado: (2019)

Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone
por: Webster, Lynn, et al.
Publicado: (2018)

AB214. Downregulation of clusterin expression in human testicular seminoma
por: Liu, Bianjiang, et al.
Publicado: (2014)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Regulation of tumor growth by leukocyte-specific protein 1 in T cells
por: Kwon, Riri, et al.
Publicado: (2020)

IL-31 induces antitumor immunity in breast carcinoma
por: Kan, Tal, et al.
Publicado: (2020)

IFN-γ treatment protocol for MHC-I(lo)/PD-L1(+) pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential
por: Stifter, Katja, et al.
Publicado: (2020)

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance
por: Shi, Linlin, et al.
Publicado: (2020)

2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1
por: Chen, Zhanfei, et al.
Publicado: (2020)

Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy
por: Bao, Xuanwen, et al.
Publicado: (2020)

Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions
por: Russick, Jules, et al.
Publicado: (2020)

Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway
por: van Pul, Kim M, et al.
Publicado: (2020)

Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models
por: van Elsas, Marit, et al.
Publicado: (2020)

CD8(+)CD57(+) T cells exhibit distinct features in human non-small cell lung cancer
por: Huang, Bing, et al.
Publicado: (2020)

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens
por: Arribillaga, Laura, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jlp5qp45rdcld7ag00j0o6jaep